CapitalBio TB Tests Cleared in China | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Molecular diagnostics and genetic analysis products developer CapitalBio has received certification from China's State Food and Drug Administration for two microarray-based tests and for one amplification-based test for tuberculosis.

The two microarray assays can identify tuberculosis from spit samples, and they were developed for use with the company's LuxScan scanning and analysis tools, according to firm, which is based in Beijing.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.